NDATOPICALGEL
Approved
Aug 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
6/8 — Strong
VALCHLOR (mechlorethamine hydrochloride) by Helsinn is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 2013.
Drug data last refreshed 2h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALCHLOR is a topical gel formulation of mechlorethamine hydrochloride, an alkylating agent approved in 2013 for cutaneous T-cell lymphoma. It works by directly damaging DNA through alkylation, disrupting cancer cell growth and division. The topical route enables localized delivery to skin lesions while minimizing systemic exposure.
$13MPart D
Peak3.0 years to LOEThe product is at peak commercial maturity with modest Medicare spend ($13M), indicating a stable but niche franchise requiring focused brand management.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Started Dec 2023
10 enrolled
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Why This Matters for Your Career
Worked on VALCHLOR at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.